GSA Capital Partners LLP Acquires New Stake in Avantor, Inc. $AVTR

GSA Capital Partners LLP bought a new position in Avantor, Inc. (NYSE:AVTR) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 80,841 shares of the company’s stock, valued at approximately $800,000.

Several other institutional investors have also modified their holdings of AVTR. Royal Bank of Canada boosted its stake in Avantor by 104.3% during the first quarter. Royal Bank of Canada now owns 203,738 shares of the company’s stock worth $3,302,000 after buying an additional 104,022 shares during the period. Empowered Funds LLC boosted its position in shares of Avantor by 40.3% during the 1st quarter. Empowered Funds LLC now owns 17,659 shares of the company’s stock worth $286,000 after purchasing an additional 5,075 shares during the period. Cetera Investment Advisers boosted its position in shares of Avantor by 40.2% during the 2nd quarter. Cetera Investment Advisers now owns 40,289 shares of the company’s stock worth $542,000 after purchasing an additional 11,543 shares during the period. Quantbot Technologies LP acquired a new stake in Avantor in the 2nd quarter valued at approximately $232,000. Finally, Arrowstreet Capital Limited Partnership raised its position in Avantor by 214.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 124,076 shares of the company’s stock valued at $1,670,000 after purchasing an additional 84,679 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

AVTR has been the topic of several research reports. Zacks Research raised Avantor from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 30th. Wells Fargo & Company boosted their price target on shares of Avantor from $14.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $13.00 target price on shares of Avantor in a research note on Thursday, July 30th. Sanford C. Bernstein started coverage on shares of Avantor in a report on Friday, June 26th. They set a “market perform” rating and a $10.50 target price on the stock. Finally, Barclays raised their price target on shares of Avantor from $7.00 to $8.00 and gave the company an “underweight” rating in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Avantor presently has an average rating of “Hold” and an average price target of $12.00.

Avantor Stock Performance

Shares of AVTR opened at $13.36 on Wednesday. The stock has a 50-day simple moving average of $11.35 and a 200-day simple moving average of $9.57. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.18 and a current ratio of 1.78. The stock has a market capitalization of $9.04 billion, a PE ratio of -15.91, a PEG ratio of 10.29 and a beta of 0.89. Avantor, Inc. has a 1 year low of $7.26 and a 1 year high of $15.93.

Avantor (NYSE:AVTR) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The business had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.61 billion. During the same period in the previous year, the company posted $0.24 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, analysts predict that Avantor, Inc. will post 0.81 earnings per share for the current fiscal year.

Avantor Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.